Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc

JAZZ

Market Cap$6.66B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Jazz Pharmaceuticals plcJazz Pharmaceuticals plc13.7-12%1.71.3
$215.00

Target Price by Analysts

94.9% upsideJazz Pharmaceuticals plc Target Price DetailsTarget Price
$249.48

Current Fair Value

126.1% upside

Undervalued by 126.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$6.66 Billion
Enterprise Value$10.25 Billion
Dividend Yield$0 (0%)
Earnings per Share$9.06
Beta0.38
Outstanding Shares60,979,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio13.67
PEG2.56
Price to Sales1.67
Price to Book Ratio1.62
Enterprise Value to Revenue2.52
Enterprise Value to EBIT17.25
Enterprise Value to Net Income21
Total Debt to Enterprise0.53
Debt to Equity1.31

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Jazz Pharmaceuticals plc

1,210 employees

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...